SHP099, as a specific inhibitor of SHP2, is widely known for its high efficacy against tumors.[23, 24, 38, 39] Tumors are the major high‐risk factor for thrombosis, and tumor‐associated thrombosis (TAT) has gradually become a major risk factor for VTE in cancer patients. This evidence concerns the gene PTPN11 and neoplasm.